Compare Novo Nordisk A/S (NVO) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard High Dividend Yield ETF — how do they compare? Novo Nordisk A/S trades at $38.49 (market cap $165.31B), while Vanguard High Dividend Yield ETF trades at $158.52 (market cap $100.80B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| NVO | VYM | |
|---|---|---|
Market Cap | $165.31B | $100.80B |
Volume | 11,432,838 | 908,176 |
Sector | Health | — |
52-Week High | $63.98 | $167.03 |
52-Week Low | $35.29 | $137.47 |
Typical Hold Time | 116 Days | 138 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
VYM trades at $158.56, up 0.7% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD and IDV. Support sits at $156, with resistance at $159-160. Recent news questions its stock selection methodology after holding Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include sector concentration in dividend-cut-prone stocks and inflation persistence. Opportunities lie in its low expense ratio and broad diversification across nearly 600 holdings for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
